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Background. Calcium channel blockers (CCBs) are known to
have differential effects on both changes in proteinuria as well as
progression of diabetic nephropathy. No clinical study, however,
has evaluated whether the differential antiproteinuric effects of
CCBs may be explained by their effect on glomerular membrane
permeability. We, therefore, tested the hypothesis that certain
subclasses of CCBs reduce proteinuria by changing size selectivity
of the glomerular membrane, hence changing its permeability.
Methods. Twenty-one patients with type 2 diabetes and the
presence of nephropathy with hypertension were randomized to
receive either diltiazem CD or nifedipine GITS after baseline data
for mean systolic and diastolic pressure, urinary protein excretion,
glomerular filtration rate, renal plasma flow, neutral dextran and
IgG clearances were obtained. Glomerular filtration rate, renal
plasma flow, neutral dextran and IgG clearance were measured
every three months, arterial pressure and heart rate every month.
Patients were followed for 21 months.
Results. At 21 months, both patient groups had similar levels of
blood pressure control, however, only the diltiazem group had a
change in proteinuria (4 6 10%D, nifedipine vs. 257 6 18%D,
diltiazem; P , 0.001) with improvement in glomerular size
selectivity and change in IgG clearance.
Conclusions. These data support the hypothesis that CCBs that
provide sustained reductions in proteinuria do so, in part, by
improving glomerular size permselectivity.
At comparable levels of blood pressure control, reduc-
tions in proteinuria and/or blunted increases in microalbu-
minuria correlate strongly with both a reduced progression
of diabetic nephropathy as well as a reduction in cardio-
vascular mortality [1–3]. Angiotensin converting enzyme
(ACE) inhibitors and angiotensin receptor antagonists
consistently reduce urinary protein excretion in the pres-
ence of moderate to low sodium diets [4–7]. Conversely,
the data from long-term clinical trials with calcium channel
blockers (CCBs) demonstrates that their antiproteinuric
effects are variable.
Recent data support the concept that nondihydropyri-
dine (nonDHP) CCBs consistently reduce or blunt the rise
in proteinuria in patients with type II diabetes who ingest a
low to moderate sodium intake [8, 9]. Conversely, dihydro-
pyridine (DHP) CCBs, regardless of their duration of
action, tend to have neutral effects on proteinuria [6,
10–12]. This latter observation is supported by most liter-
ature with the exception of one small, single center study
[13]. In this study, the glomerular filtration rate (GFR)
declined with administration of amlodipine to the same
degree as the ACE inhibitor. This is contrary to reported
studies of greater than one-year duration [11, 14].
The present study examines the hypothesis that the
nonDHP CCB, diltiazem CD reduces glomerular mem-
brane permeability to high molecular weight species com-
pared to the DHP CCB, nifedipine. Hence, the nonDHP
CCB will reduce proteinuria. This change in membrane
permeability is assessed by changes in glomerular size and
charge selectivity. The data from this study form the basis
of this report.
METHODS
The Institutional Review Boards of both Holy Family
Hospital and Rush-Presbyterian-St. Luke’s Medical Center
approved the study protocol, where the study was con-
ducted. All participants signed informed consents prior to
entry into the study.
Study design
The inclusion and exclusion criteria for study participa-
tion are summarized in Table 1. Sixty-seven subjects were
screened from both medical centers, 28 of whom were
found eligible and consented to participate in the study.
The baseline characteristics of the study participants are
shown in Table 2. Of these, 21 completed the entire study
and 15 of 21 participants completed all dextran clearance
measurements. The baseline characteristics of both the
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dropouts and those that did not complete the dextran
measurements are summarized in Table 3. The primary
reasons for dropouts during the study were related to drug
side effects and summarized in Table 4. Moreover, the
primary reason for only 76% participant completion of all
dextran measurements related primarily to either a history
of specific allergies to sulfa or penicillin type drugs or
development of allergic reactions during a dextran study.
Two of the six patients who did not complete the dextran
studies developed an anaphalactoid type reaction during
the study. The four remaining participants had previously
mentioned drug allergies and refused to undergo the
dextran clearance procedures.
The study design is illustrated in Figure 1. After a
two-week washout period off their current antihypertensive
medications, baseline measurements of arterial pressure,
fasting blood glucose, serum IgG levels and hemoglobin
A1c were assessed. Additionally, glomerular filtration rate
(GFR) as measured by inulin clearance, renal plasma flow
(RPF) as assessed by para-aminohippurate clearance, dex-
tran clearance along with 24-hour urinary protein, albumin
and IgG excretion were measured. Participants were then
randomized to receive either nifedipine or diltiazem in a
once daily preparation to achieve a goal blood pressure
of , 140/90 mm Hg. These agents were titrated to achieve
a blood pressure goal of , 140/90 mm Hg or until a
maximum dose of 90 mg or 480 mg per day of nifedipine or
diltiazem, respectively was attained. If blood pressure goal
was not achieved, furosemide, 40 milligrams once daily, was
added. If control was still inadequate, clonidine, at a
starting dose of 0.1 mg twice daily, was added and titrated
upwards. Furosemide was selected to help restore volume
homeostasis, a well-known problem in with diabetes and
renal insufficiency [15]. Clonidine was selected due to its
neutral effects on proteinuria [16]. After blood pressure
control was achieved, participants had monthly follow-up
visits to insure appropriate blood pressure control and
medication compliance. Additionally, they returned every
three months for measurement of GFR, RPF, and 24-hour
urinary determinations of total protein, albumin and so-
dium excretion rates. Additionally, every six months IgG
and dextran clearances were assessed.
Following baseline measurements of all variables, all
Table 1. Inclusion and exclusion criteria
Inclusion criteria
z .4 year history of type II diabetes
z .4 year history of hypertension ($140/90 mmHg)
z .300 mg/day proteinuria
z Age $ 45 years
Exclusion criteria
Presence of:
z Secondary cause of hypertension
z Serum creatinine $2.5 mg/dl
z Clinically apparent congestive heart failure or ejection fraction
,40%
z Stroke or myocardial infarction within the past year
z History of allergic reaction to study drugs
z Terminal diseases including cancer or AIDS
z Collagen vascular diseases
z Serum creatinine increase .20% over baseline within one month of
study entry
z Required ingestion of ACE inhibitor, CCBs or anti-arrhythmic
medications
z Psychiatric illness or mental retardation
Table 2. Baseline characteristics of all recruited participants
Variable
Nifedipine
(N 5 14)
Diltiazem
(N 5 14)
M/F 11/3 13/1
Age years 57 6 4 59 6 8
Caucasian % 100 93
Diabetes Hx. years 12 6 5 10 6 4
Hypertension Hx. years 14 6 6 13 6 5
Body Weighta kg 91 6 6 88 6 7
Family Hx. CVD % 85 100
Smoking Hx. % 36 50
ACEI naı¨ve % 86 79
a Based on height, 89% of the participants were greater than 20% above
ideal body weight
Table 3. Baseline characteristics of participants who did not complete
the study including dextran clearance studies
Variable
Nifedipine
(N 5 7)
Diltiazem
(N 5 6)
Demographic
M/F 3/4 5/1
Age years 60 6 5 62 6 4
Caucasian % 86 83
Diabetes Hx. years 14 6 6 12 6 7
Hypertension Hx. years 12 6 5 15 6 6
Body weighta kg 85 6 9 83 6 8
Family Hx. CVD % 86 100
Smoking Hx. % 43 33
ACEI naı¨ve % 57 50
Hemodynamic
Systolic pressure mm Hg 179 6 8 185 6 7
Diastolic pressure mm Hg 99 6 5 102 6 5
GFR ml/min/1.73 m2 88 6 11 91 6 8
Uprotein V mg/day 636 6 194 784 6 206
a Based on height, 62% of the participants were greater than 20% above
ideal body weight
Table 4. Adverse events and reasons for study withdrawal
Nifedipine
(N 5 14)
Diltiazem
(N 5 14)
Number not completing study 4 (29) 3 (21)
Adverse events
Pedal edema 3 (21) 1 (7)
Headache 1 (7) 0
Gingival hyperplasia 1 (7) 0
Worsening DM 2 (14) 0
Nausea 1 (7) 1 (7)
Stroke 1 (7) 0
Rash 0 1 (7)
Number in parenthesis indicates the percent of a particular adverse
event.
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participants were counseled to follow moderately low so-
dium, that is, ,120 mEq per day sodium diet. To improve
compliance with the diet, it was reviewed at each visit.
Moreover, participants were informed that we would assess
sodium intake through urinary determinations.
Renal hemodynamic measurements
In each case urine was voided spontaneously after diure-
sis had been established with oral water loading. A priming
infusion containing 10% inulin (30 mg/kg), neutral dextrans
(140 mg/kg) and 20% sodium para-aminohippuric acid
(PAH, 8 mg/kg) was then administered over 30 minutes.
Thereafter, inulin, PAH and neutral dextrans were contin-
uously infused to maintain plasma levels constant at 20 and
1.5 mg/dl of inulin and PAH, respectively. Four carefully
timed urine collections were then made, each of which was
bracketed by blood samples drawn from a peripheral vein.
The average inulin clearance for the timed collection
periods was taken to represent the GFR.
Plasma and urine concentration of PAH and inulin for
determination of RPF and GFR, respectively, were mea-
sured as previously described [17]. Plasma and urine sam-
ples for dextran sieving were analyzed by previously pub-
lished methods [18]. Briefly, urine and plasma samples
were deproteinized with ZnSO4 and 0.75 N NaOH. The
samples were centrifuged at 4°C for 10 minutes and the
supernatant was decanted, recentrifuged then dehydrated
by Speed-vac overnight, reconstituted and prefiltered. Sep-
aration of dextrans into narrow fractions was performed by
HPLC (Beckman Instruments, Fullerton, CA, USA) using
Ultragel 500 and 250 columns in series (Millipore, Milford,
MA, USA). The columns were calibrated with four nar-
rowly dispersed dextrans of known molecular weight (10,
20, 40, 70). Dextran concentration was measured using an
on-line UV detector (Model 156; Beckman Instruments
Inc.). Chromatograms were translated into a PRN file and
the area under the curve for the region of interest corre-
sponding to 32 to 70 angstroms (Å) was analyzed by
SigmaPlot for Windows version 2.0 (Jandel Scientific Soft-
ware, San Rafael, CA, USA). Sieving curves were con-
structed from slices taken at 2.0 Å increments and the area
for each slice equated with the dextran concentration at the
corresponding retention time. Fractional dextran clearance
at each radius (um) was computed from the first timed
collection using the equation
um 5 Udextran z Pinulin/Uinulin z Pdextran
where the urine-to-midpoint plasma concentration ratio of
sized dextran was assessed. Additionally, the clearances of
other macromolecules that is, albumin and IgG, were also
assessed in the same way.
IgG concentrations were measured by nephrolometry
(Behring Diagnostics, San Jose, CA, USA). Samples un-
derwent electrophoresis, using lazer analysis, to determine
total IgG concentrations.
Statistical analysis
The study was designed with 80% power to detect a 30%
difference in proteinuria reduction from baseline levels
between CCB groups. We assumed a five percent reduction
in the nifedipine group. Proteinuria, however, increased in
the nifedipine group by 4.6%. Therefore, the power to
detect a 30% reduction was adequate.
All data are expressed as mean 6 SD from the mean.
Comparisons between groups with regard to proteinuria
and demographic characteristics were assessed by an anal-
ysis of variance. Even with adequate power, we used a
Bonferonni correction in our analyses to reduce the prob-
ability of committing a Type I error. Differences between
groups with regard to dextran and IgG clearances were
assessed by a Student’s t-test comparing baseline to 21-
month values. Differences between groups were evaluated
Fig. 1. Illustrated protocol. Abbreviations are: CCBs, calcium channel blockers; BP, blood pressure.
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for clearances of dextran molecules of various sizes ranging
from 30 to 60 Å. Differences were regarded as significant
when P , 0.05.
RESULTS
General
The baseline systemic and renal hemodynamic as well as
metabolic profile of the participants who completed the
study is listed in Table 5. There were no significant differ-
ences between any baseline values between groups. More-
over, a comparison of the demographic features between
those who completed the study versus dropouts failed to
reveal any significant difference between groups. However,
the dropout group tended to be slightly older with a female
preponderance in the nifedipine group.
The trends in arterial pressure, proteinuria and HbA1c
are summarized in Figures 2 to 4. No significant differences
were noted between groups with regard to either of these
variables at any time points measured throughout the
study. Moreover, to achieve adequate blood pressure con-
trol each person ingested an average of 2.6 and 2.8 different
antihypertensive agents in the nifedipine and diltiazem
groups, respectively. The breakdown of doses and types of
agents used are summarized in Table 6. Compliance with
sodium intake is found in Table 5. No significant differ-
ences in sodium intake were noted between groups.
Renal hemodynamics
GFR and RPF were not significantly altered over the
21-month period of study in either group (Table 5). The
changes in proteinuria at baseline and study-end are also
noted in Table 5. Trends in proteinuria changes in each
patient that completed the study are illustrated in Figure 4.
Clear differences at 21 months were noted between groups
in the amount of proteinuria change from baseline (4 6
10%D, nifedipine vs. 257 6 18%D, diltiazem, P , 0.001).
Furthermore, only the group randomized to diltiazem
manifested a reduced clearance with too large sized dex-
trans ($ 50 Å) at 21 months (Fig. 5).
Reduction in dextran clearance was paralleled by a
reduction in IgG clearance in the diltiazem group (5.9 6
2.3, baseline vs. 2.6 6 1.7 3 1025, 21 months; P , 0.05).
IgG clearance was not reduced in the nifedipine group
(7.6 6 3.1, baseline vs. 11.2 6 4.3 3 1025, 21 months; P 5
1.8). The change in clearance of large sized dextrans was
Fig. 2. Effects of nifedipine (A) or diltiazem (B) in a once daily dosage
formulation on HbA1c throughout the study period in each patient.
Table 5. Baseline and 21 month systemic and renal hemodynamic, metabolic profiles of 21 patients with NIDDM nephropathy
Nifedipine XL (N 5 10) Diltiazem CD (N 5 11)
Baseline 21 Months Baseline 21 Months
Arterial pressure
Systolic mm Hg 172 6 11 136 6 9a 182 6 12 138 6 9a
Diastolic mm Hg 106 6 6 84 6 5a 104 6 6 86 6 7a
Renal
GFR ml/min/1.73 m2 94 6 8 91 6 9 98 6 7 101 6 9
RPF ml/min/1.73 m2 397 6 31 434 6 32 448 6 34 472 6 36
Uprotein V mg/day 873 6 167 905 6 208 908 6 234 389 6 127
a
Usodium V mmol/day 171 6 32 136 6 37 158 6 28 129 6 32
UIgG V mg/dl 0.72 6 0.27 0.98 6 0.36 0.65 6 0.22 0.29 6 0.17
a
Metabolic
FBS mg/dl 178 6 16 165 6 18 192 6 13 171 6 15
HbA1c
b % 8.9 6 0.7 8.2 6 0.8 9.4 6 0.8 8.5 6 0.7
Abbreviations are: FBS, fasting blood sugar; GFR, glomerular filtration rate; RPF, renal plasma flow.
a P , 0.05 compared to baseline values. b Normal range for HbA1c are 3.8–6.2%
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not significant, however, until one year after the study
started (Fig. 5). Moreover, the trends in size selectivity
change continued until study end, although they were not
significantly different from those at one year the the larger
sized dextrans (Fig. 5). This reduction in clearance of large
sized dextrans correlated with reductions in proteinuria at
21 months (r 5 0.62; P , 0.03). This correlation was not
present at six months but was detectable at one year (r 5
0.49; P , 0.05). Additionally, the change in proteinuria
from baseline did not become significant in the diltiazem
group until six months after the study started (Fig. 4).
Therefore, changes in membrane permeability account for
only part of the benefit in proteinuria change.
DISCUSSION
This study provides the first evidence to explain differ-
ences in antiproteinuric effects between subclasses of CCBs
in participants with nephropathy from type 2 diabetes.
While some of the early changes in proteinuria in the
diltiazem group may be ascribed to hemodynamic changes,
that is, blood pressure reduction, this does not explain the
entire effect, since proteinuria was not reduced with nifed-
ipine. It is clear that changes in membrane size selectivity
also contribute significantly to this antiproteinuric effect.
The changes in size selectivity especilly to large sized
dextrans begin to occur as early as six months after
diltiazem is initiated but do not become significant until
one year. Moreover, these reductions in dextran clearance
to large sized dextrans continue for at least another nine
months. These changes in membrane size selectivity corre-
late with changes in proteinuria in participants treated with
diltiazem but not nifedipine. This contrast in proteinuria
reduction could not be explained by differences in blood
pressure at any time point or other baseline demographic
data. Moreover, our data on size selectivity and proteinuria
extend the findings of Hartmann et al, who failed to
demonstrate a reduction in proteinuria or size permselec-
tivity among participants with hypertension and non-dia-
betic renal disease that received nifedipine [19]. Thus, our
data, taken together with other human and animal studies,
strongly supports the notion that DHP CCBs do not affect
glomerular permeability and hence, proteinuria [2, 20, 21].
Previous studies have clearly established the utility of
dextran clearance as a method of determining size selective
properties of the glomerular capillary wall (GCW) [22, 23].
These studies demonstrate that those with proteinuria have
an increased transglomerular passage of dextrans with a
radius of . 50 Å [24]. Our data support this observation.
Moreover, it is the reduction in transglomerular passage of
these larger sized dextrans that primarily account for the
attenuated increase in proteinuria that is observed with
diltiazem. Additionally, a reduction in IgG clearance fur-
ther supports the concept of altered permeability of the
GCW. According to pore theory, this reduction in perme-
ability is presumably due to an expansion of the minor
region of the GCW that behaves as a non-restrictive shunt
pathway [22].
Reductions in proteinuria are important in diabetes since
they have been associated with a slowed progression of
renal disease [2]. Evidence from a post hoc analysis of The
Captopril trial by Hebert et al demonstrate that individuals
with reductions in nephrotic range proteinuria manifested a
remission in renal disease [1]. Moreover, we and others
have demonstrated that among patients with diabetic ne-
phropathy those who manifest reductions in proteinuria
also manifest a slowing in nephropathy progression [8, 9,
25]. Additionally, both animal and human studies reveal
that blood pressure control without proteinuria reduction
does not slow progression of nephropathy [11, 26, 27].
Thus, while blood pressure reduction is clearly important in
patients with diabetic nephropathy, reduction in protein-
uria must also be a consideration to optimally preserve
renal function.
Another possible explanation for the differences in pro-
teinuria reduction between these two CCBs might be
differences in intrarenal hemodynamic effects. In vitro
studies reveal that while diltiazem dilates both the afferent
and efferent arterioles, nifedipine does not [28, 29]. How-
ever, in animal models of diabetes these CCBs [27, 30] do
not reduce increases in intraglomerular pressure that result
from both afferent dilation and efferent arteriole constric-
tion. Thus, differences in intrarenal hemodynamics do not
Fig. 3. Effects of nifedipine (A) or diltiazem (B) in a once daily dosage
formulation on mean arterial pressure throughout the study period in
each patient.
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explain the variance in antiproteinuric effect between these
two different CCBs.
The level of blood pressure achieved may also create
differences in intrarenal hemodynamics. One animal study
has demonstrated that nonDHP CCBs reduce efferent
arteriolar tone and intraglomerular pressure [31]. How-
ever, blood pressure in these animals was profoundly
reduced. Conversely, this has not been shown with either
nifedipine or amlodipine [27, 32]. In clinical studies of
patients with nephropathy, the level of blood pressure
reduction also seems to affect progression of nephropathy
[33, 34]. We did not randomize to different levels of blood
pressure control, however, nor was there a difference in
blood pressure control throughout our study. Moreover,
based on animal data this would not have had an impact on
outcome since nifedipine did not appear to protect the
kidney even at lower blood pressures.
Other possible explanations for the differential effects of
CCBs on proteinuria include (a) a differential distribution
of calcium channels on the GCW, and (b) differential
effects of CCBs on various structural proteins such as
heparan sulfate of glucosaminoglycan or differences in
autoregulatory responses of the kidney [35–37]. Animal
experiments in diabetic animals clearly demonstrate an
attenuated decrease in both glucosaminoglycan and hepa-
ran sulfate by diltiazem [38]. Moreover, nonDHP CCBs
have been shown to blunt the increase in mesangial matrix
expansion and proteinuria in animal model of diabetes [39].
Thus, diltiazem appears to have properties that affect
Fig. 4. Effects of diltiazem (A) or nifedipine
(B) in a once daily dosage formulation on
urinary protein excretion throughout the study
period in each patient.
Table 6. Distribution of all antihypertensive agents used in study
including the mean dose of each
Nifedipine
(N 5 10)
Diltiazem
(N 5 11)
Mean dose of randomized drug mg 78 6 12 436 6 43
Mean dose of furosemide mg 40 (9) 40 (11)
Mean daily dose of clonidinea mg 0.29 6 0.07 (4) 0.25 6 0.04 (3)
Numbers in parentheses indicate number of people in group receiving
this medication. Randomized drug was titrated to maximum prior to
addition of other agents.
a Half the dose given twice daily
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glomerular permselectivity in different ways than nifedi-
pine. This helps explain the differential effects of these two
agents on proteinuria.
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APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; CCBs, calcium channel blockers; DHP, dihydropyridine; GCW,
glomerular capillary wall; GFR, glomerular filtration rate; HPLC, high-
pressure liquid chromatography; nonDHP, nondihydropyridine; PAH,
para-aminohippuric acid; RPF, renal plasma flow.
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